All
New Drug Granted a Priority Review for AML Treatment
June 2nd 2017VYXEOS (CPX-351), a novel injection, was granted a new drug application (NDA) by the Food and Drug Administration (FDA), granting the drug a priority review for the treatment of acute myeloid leukemia (AML), according to Jazz Pharmaceuticals, the producer of the drug.
Combination Improves Progression-Free Survival in Urothelial Carcinoma
June 1st 2017According to results from the phase 3 RANGE trial, the addition of Cyramza (ramucirumab) to docetaxel resulted in improved progression-free survival for patients with previously treated locally advanced or unresectable or metastatic urothelial carcinoma.
Using a Virus to Boost Immunotherapy Response in Melanoma
May 31st 2017Patients with in immunotherapy-naïve and pretreated patients with advanced melanoma saw a 50 percent overall response rate (ORR) when adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to Yervoy (ipilimumab) – a combination which was well-tolerated.